INVESTIGATION ON HORMONAL DEPENDENCY OF PROSTATE TUMORS
Main researcher
: TARLE, MARKO (71894) Assistants
KOVAČIĆ, KSENIJA (142680)
KRALJIĆ, IVAN (127084)
FRKOVIĆ-GRAZIO, SNJEŽANA (175394)
ČULIG, ZORAN (175192)
ANZULOVIĆ, ZDRAVKO (120635)
FERENČIĆ, ŽELJKO (178724)
PLASAJ, TOMISLAV (89130)
BALIČEVIĆ, DRINKO (149553)
Type of research: applied Duration from: 01/01/91. to 12/31/94. Papers on project (total): 35
Papers on project quoted in Current Contents: 25
Institution name: Bolnica "Sestre milosrdnice", Zagreb (134) Department/Institute: Division of prostate tumors diagnosis and monitoring, Clinic of Nuclear Medicine and Oncology, Univ.Hosp.Sestre Milosrdnice, Address: Vinogradska c. 29 City: 10000 - Zagreb, Croatia
Communication
Phone: 385 (41)174666-228
Fax: 385 (41) 172 453
Phone: 385 (0)
Phone: 385 (0)
Phone: 385 (41) 174666-228
Fax: 385 (41) 172 453
Summary: The relationship between serum osteocalcin and cortisol
level was studied in hormonally treated and progressive prostate cancer
patients. Neuroendocrine structures in adenocarcinoma that increase serum
NSE (and CEA) level are found to refractory to androgen deprivation. NK
values measured under in vivo conditions are recognized as a sensitive
probe for circulating tumor cells. Blood TPS value is found to be the
valuable tool in monitoring metastatic patients. Correlation between serum
PSA level and a decreased tumor differentiation in hormonally treated and
progressive subjects gave a bell-shaped curve with the maximum associated
with moderately differentiated tumors. In ongoing studies we investigate
the recognition of small cell cancer structures within adenocarcinoma by
assessing circulating TPS, PSA, PAP, NSE levels and tissue chromogranin A
marker, the relationship between the increase in serum TPS level and a
loss in tumor differentiation, the development of 'pure'small cell
prostate tumor and sarcomatoid tumor from high grade adenocarcinoma by a
serial measurement of specific immunohistochemical markers and tumor
serotests, the pronounced and transient peak in serum TPS level that was
found in over 50% of responders to androgen deprivation with well and
moderately differentiated tumors, immunohistochemical studies of benign
hypertrophy, prostatic intraepithelial neoplasia, low and high grade
carcinom of the prostate by using a wide spectrum of tissue and serum
markers, mechanism of action of flutamide monotherapy in relations to
apoptosis. In the years 1994/95 treatment of poorly differentiated cancer
by applying maximal androgen blockade was studied. The role of TPS
serotest was redefined as a marker of circulating tumor cell or their
degradation products. The investigation of free(F), bound (B) and total
(T) blood PSA fraction gave an excellent parameter (F/T)x100 PSA used for
the distinction of really benign atypical prostate from the same entity
that will progress soon into aggressive metastatic cancer. This same
parameter was found to be exceedingly useful prognostic index during
monitoring treated patients with prostatic carcinoma. This parameter is
already clinically used. Serotest PSA, PAP, TPS, TPA, (F/T)x100 PSA and NK
cell activity data are studied in subjects treated with cytotoxic drugs
such as 5-FU, endoxan or their combination.
Keywords: Prostate cancer, immunohistochemical and serotest markers, NK activity, proliferation, apoptosis, PSA, PAP, CEA, NSE, TPS, cytokeratins, chromogranin A, osteocalcin, early diagnosis, monitoring protocols, total andogen blockade,cytotoxic treatment,(F/T)x100 PSA, diagnosis, treatment.
Research goals: During the past decade this project was aimed at
theinvestigation of natural history of prostate cancer. 1. Onlya small
fraction of prostatic tumor are initially manifest. Themajority remains
silent during lifetime.The early distinctionbetween the latent and
manifest form of cancer appears to be ofthe utmost clinical importance. 2.
Androgen deprivation is apalliative treatment due to apoptosis of
secretory cells whilebasal cells, being androgen independent, remain
intact. Thesecells are the potential source of hormone refractory cancer.
Weinvestigate the appearance of hormonally independent carcinomaafter
relapse of hormone dependent disease by assessing tissuecytokeratin
expression together with other relevant markers.3.Endocrine cells regulate
tumor proliferation by the paracrineaction. We investigate the
development of aggressiveneuroendorine tumors. 4. Protocols that use PSA
and PAP serotestsfor monitoring poorly differentiated carcinomas are of
limitedclinical use due to hormonal dependency of these markers. Westudy
the clinical application of cell proliferation markers inhormonally
treated patients. 5. Apoptosis is investigated inprostatic adenocarcinoma
by using immunohistochemical andserotest markers. The obtained data are
already used in clinical practice. In the period 1994/95 studies were
aimed at 1.monitoring of cytotoxic treatment (5-FU, endoxan) by appying
PSA. PAP, TPS, NK cell activity data,and a new (F/T)x100 PSA parameter;2.
the application of free (F), bound (B), and total (T) PSA fraction in the
circulation that expressed as (F/T)x100 PSA value is useful in
differentiating benign atypical prostate from the same that is already
transformed into aggressive and metastatic cancer; 3. this same parameter
is studied with success as a prognostic index in monitoring treated
patients with prostatic carcinoma; 4.data that inform us on the usefulness
of the maximal androgen blockade in patients with a high Gleason score
cancer (>6). Other information about the project.